Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹6,850 Cr
verified against source
Revenue YoY
9.9%
reported change
EBITDA
₹1,151.4 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Aurobindo Pharma delivered a robust Q1 FY24 with revenue of INR 6,850 crore (+9.9% YoY) and EBITDA of INR 1,151 crore (+19.3% YoY), driven by strong US formulation growth (+11.2% YoY to $402M) and a record European quarter (EUR 205M, +18.6% YoY). EBITDA margin expanded to 16.8%, supported by operating leverage and stable US pricing. Management targets 18%+ EBITDA margin for FY24 (ex-Revlimid) and expects further improvement from export benefit normalization and Puerto Rico restructuring. The injectable business (Eugia) aims for $500M+ revenue this year, with Revlimid launch from October 1 as an additional opportunity. Key risks include potential pricing pressure in US generics and delayed ramp-up of PLI Pen-G capacity.
Colored figures show movement against the previous available record.
Guidance to track
- Management targets 18%+ EBITDA margin for FY24, excluding Revlimid contribution, supported by operating leverage and export benefit normalization.
- Eugia aims to achieve $500M+ global revenue in FY24, up from $411M pro forma last year, excluding Revlimid.
- PLI facilities and investments targeted to be completed before 1st April 2024, with full ramp-up expected by mid-FY25.
- First oncology biosimilar launch in India expected this year, with multiple launches in regulated markets from FY25 onwards.
Risks flagged
- While pricing has stabilized recently, any reversal could pressure US margins and revenue growth.
- As a late entrant, Aurobindo's Revlimid volume share is expected to be lower than early entrants, limiting upside.
- Management acknowledged that full ramp-up of Pen-G capacity may take time, with clarity only expected by February 2024.
- Management declined to provide revenue projections for biosimilars, citing evolving market dynamics, indicating high uncertainty.
Key quotes
- Our endeavor is to achieve an internal target of 18+% EBITDA for the year, plus margin on special product.
- We treat Revlimid as one of opportunity, and so we will just keep that... we will launch it from October 1, that's the settlement date.
- The real driver of the performance has been orals. Because of our broad product portfolio and excellent customer coverage, we are in a better position to gain market share when the competitors have shortages.
Research modules